BioPharm International-01-01-2021

BioPharm International

BioPharm International's January 2021 issue, Volume 34, Number 1

Biopharma Gets Back to “New Normal” Business

January 02, 2021

Cover Story

34

01

After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.

Compensation Does Not Necessarily Align with Job Satisfaction

January 02, 2021

Special Coverage

34

01

Essential bio/pharma employees show hard work and dedication can pay off, for patients.

Can Cell and Gene Therapies Achieve Their Full Potential?

January 02, 2021

Development

34

01

Advances in development, data management, and automation, and closer collaboration with contract development and manufacturing partners, are pushing more therapies closer to commercialization.

Cultivating a Synthetic Biology-Based Approach to Improving Cell Culture

January 02, 2021

Upstream Processing

34

01

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

EASY: a Disruptive mAb Purification Process to Reduce Cost of Goods

January 02, 2021

Downstream Processing

34

01

The development of an innovative purification process simplifies downstream processing for biologics.

The Importance of Process Intensification and PAT for Achieving Real-Time Release

January 01, 2021

Manufacturing

34

01

Creativity and collaboration are required to overcome complex method development challenges.

Accelerating Technology Adoption to Track the Cold Chain

January 01, 2021

Quality/Regulations

34

01

Packaging and transporting large quantities of COVID-19 vaccines pose challenges for the cold chain.

Using Protein Characterization to Support Regulatory Submissions

January 01, 2021

Analytics

34

01

Clear understanding of what exactly the biomolecule entails is essential.

Supporting the Industry During a Pandemic

January 01, 2021

Outsourcing

34

01

Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.

Pandemic Control to Shape Biopharma in 2021

January 01, 2021

Regulatory Beat

34

01

The incoming administration faces key decisions on drug testing and access as well as vaccine distribution challenges.

Ensuring Vaccine Supply Meets Need

January 01, 2021

From the Editor

34

01

Shutting down the COVID-19 pandemic requires a global, selfless effort.

Now is the Time to Update the Quality Technical Agreement

January 01, 2021

Ask The Expert

34

01

Updating the quality technical agreement will clarify any expectations and limitations, says Siegfried Schmitt, vice president, Technical at Parexel.